These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 27184479)
21. Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components. Mishima C; Kagara N; Ikeda JI; Morii E; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S Am J Pathol; 2018 May; 188(5):1106-1112. PubMed ID: 29454754 [TBL] [Abstract][Full Text] [Related]
22. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value. Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442 [TBL] [Abstract][Full Text] [Related]
23. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer. Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293 [TBL] [Abstract][Full Text] [Related]
24. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer. Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192 [TBL] [Abstract][Full Text] [Related]
25. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585 [TBL] [Abstract][Full Text] [Related]
28. PIK3CA mutations in mucinous cystic neoplasms of the pancreas. Garcia-Carracedo D; Chen ZM; Qiu W; Huang AS; Tang SM; Hruban RH; Su GH Pancreas; 2014 Mar; 43(2):245-9. PubMed ID: 24518503 [TBL] [Abstract][Full Text] [Related]
29. Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA. Shalmon B; Drendel M; Wolf M; Hirshberg A; Cohen Y Int J Oral Maxillofac Surg; 2016 Jun; 45(6):721-5. PubMed ID: 26811072 [TBL] [Abstract][Full Text] [Related]
30. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277 [TBL] [Abstract][Full Text] [Related]
31. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936 [TBL] [Abstract][Full Text] [Related]
32. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma]. Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825 [TBL] [Abstract][Full Text] [Related]
33. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3. Sakane T; Murase T; Okuda K; Saida K; Masaki A; Yamada T; Saito Y; Nakanishi R; Inagaki H Histopathology; 2019 Nov; 75(5):755-766. PubMed ID: 31179560 [TBL] [Abstract][Full Text] [Related]
34. [Anatomoclinical and immunohistochemical study of hidradenoma papilliferum, a tumor deriving from anogenital mammary-like glands]. Blind A; Weingertner N; Cribier B Ann Dermatol Venereol; 2019 Sep; 146(8-9):528-536. PubMed ID: 31285043 [TBL] [Abstract][Full Text] [Related]
35. A novel fusion gene CRTC3-MAML2 in hidradenoma: histopathological significance. Kuma Y; Yamada Y; Yamamoto H; Kohashi K; Ito T; Furue M; Oda Y Hum Pathol; 2017 Dec; 70():55-61. PubMed ID: 29079171 [TBL] [Abstract][Full Text] [Related]
36. PI3K/Akt pathway mutations in retinoblastoma. Cohen Y; Merhavi-Shoham E; Avraham-Lubin BC; Savetsky M; Frenkel S; Pe'er J; Goldenberg-Cohen N Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5054-6. PubMed ID: 19420344 [TBL] [Abstract][Full Text] [Related]
37. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant. Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889 [TBL] [Abstract][Full Text] [Related]
38. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217 [TBL] [Abstract][Full Text] [Related]
39. Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas. Je EM; An CH; Yoo NJ; Lee SH APMIS; 2012 Aug; 120(8):635-9. PubMed ID: 22779686 [TBL] [Abstract][Full Text] [Related]
40. Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shiratori K; Kawamura S; Kobayashi M; Shimizu M; Ban S; Koyama I; Higashi M; Shin N; Ishida K; Morikawa T; Motoi F; Unno M; Kanno A; Satoh K; Shimosegawa T; Orikasa H; Watanabe T; Nishimura K; Harada Y; Furukawa T Am J Surg Pathol; 2011 Dec; 35(12):1812-7. PubMed ID: 21945955 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]